- Curriculum Vitae
16-07-1998, Degree in Pharmaceutical Chemistry and Technology (108/110) at the University of Parma
27-01-2003, PhD award in “Experimental pharmacology and toxicology” with a thesis on “Pharmacological control of inflammatory processes and aggregation mechanisms”
November 1998 – November 2002, PhD student.
February 2001 – January 2005, research collaborator at the university of Parma.
February 2002 – November 2002, visiting scientist at the “Dep. of Oncology and Hematology” at the University of Pennsylvania, Philadelphia under the supervision of the professor Brass LF.
January 2005 – October 2015, researcher at the University of Parma and lecturer of Pharmacognosy.
Ocotber 2015 - today, associate professor of pahrmacology and lecturer of pharmacognosy at the department of Farmacia, Università di Parma
I began my scientific activity, when I was a student, working with isolated organ models (guinea-pig ileum and atrium) and with binding techniques that make me learn the basis of classical experimental pharmacology.
During this period I had also the chance to arrange the method of platelet aggregation, never used before in our laboratory. This experience oriented my interests towards platelets aggregation and themes related to thromboembolic diseases.
In the years of my PhD I increased the number of in vitro (coagulation, fibrinolysis, serotonin release from platelets, binding), ex vivo and in vivo (ferric chloride thrombus and disseminated thromboembolism) available tests to better study new antiplatelet and antithrombotic compounds in collaboration with chemical researchers of other Universities.
To extend my knowledge on platelet physiology and to learn new experimental techniques I spent almost a year at the University of Pennsylvania, where I had the opportunity to know the Eph-kinases, a large family of protein tyrosine kinases expressed also on platelet. I took part at the project to characterize the role of these proteins evaluating fibrinogen binding, platelet aggregation and granule secretion in response to ephrin activation and producing recombinant proteins mimicking extracellular domain of EphA4, EphB1 and ephrinB1.
While doing this work I broadened my repertoire of skills to include a good amount of molecular biology (PCR, cloning, protein production, site-directed mutagenesis, use of MacVector and Vector NTI, cell culture, cell temporary and stable transfection, Western blot, co-immunoprecipation) as well as flow cytometry.
Back from USA I took care of abandoned studies of antithrombotic compounds and at the same time I began two new projects.
The primary work was developed in collaboration with Dr Bruni (University of Parma, Dipartimento di biologia evolutiva e funzionale), a pharmaceutical biologist devoted to natural plant extracts phytochemistry and phytochemical analysis. I tested antiplatelet/antithrombotic properties of many essential oils and we discovered a relationship between antiplatelet potency and phenylpropanoids content. The most promising essential oils were following tested in “in vivo” models demonstrating their antithrombotic efficacy and their main active compounds detected and tested. I am responsible of the coordination of a small research team (a technician and 2-3 students) to perform biological tests with them. I take care to design and perform experiment, to elaborate data, to update literature and to write scientific works which are widely discussed with colleagues of my Dept.
A huge amount of new competencies in the field of natural compounds was acquired from beginning of 2006 when I had the responsibility to teach Pharmacognosy in the course of “Herbal sciences” of the University of Parma. Starting from the current year I teach Pharmacognosy to students of “Pharmacy” and “Pharmaceutical chemistry and technologies”, too. To help them in their studies I wrote a book: “Principi di Farmacognosia e Fitoterapia” (Principles of pharmacognosy and phytotherapy).
The second project is based on the experience with Eph-ephrin system. Aim of the work is to develop an EphA2-ephrinA1 ligand in order to disrupt its physiological function. In fact, such system is involved in tumoral progression and angiogenesis.
This aim will be reached through three complementary and synergic strategies: serendipity (fragment approach), in silico drug design and activity-guided fractionation.
Several low molecular weight natural compounds from molecular data bank and a large number of plant extracts, selected in order to cover the widest range of chemical structures, will be screened. An activity-guided fractionation will be performed in order to isolate and identify binding molecules from extracts displaying an adequate activity.
The most promising molecules will be characterized to investigate their agonist or antagonist activity and to assess their antitumoral effect in vitro. In vivo activity will be assessed on selected compounds in proper mice models. This work was funded by AIRC (Italian Association for Cancer Research).
Anno accademico di erogazione: 2020/2021
- Course year: 4 - Full cicle (5 years) - Pharmaceutical chemistry and technology - A.Y.: 2017/2018
- Course year: 2 - Full cicle (5 years) - PHARMACY - A.Y.: 2019/2020
- Course year: 3 - First cycle degree (DM 270) - BIOMEDICAL LABORATORY TECHNIQUES - A.Y.: 2018/2019
- Course year: 2 - First cycle degree (DM 270) - Imaging and Radiotherapy techniques - A.Y.: 2019/2020
- Course year: 1 - - DRUG SCIENCES - A.Y.: 2020/2021
Anno accademico di erogazione: 2019/2020
- Course year: 4 - Full cicle (5 years) - Pharmaceutical chemistry and technology - A.Y.: 2016/2017
- Course year: 2 - Full cicle (5 years) - PHARMACY - A.Y.: 2018/2019
- Course year: 3 - First cycle degree (DM 270) - BIOMEDICAL LABORATORY TECHNIQUES - A.Y.: 2017/2018
- Course year: 2 - First cycle degree (DM 270) - Imaging and Radiotherapy techniques - A.Y.: 2018/2019
- Course year: 1 - - DRUG SCIENCES - A.Y.: 2019/2020
Anno accademico di erogazione: 2018/2019
- Course year: 4 - Full cicle (5 years) - Pharmaceutical chemistry and technology - A.Y.: 2015/2016
- Course year: 2 - Full cicle (5 years) - PHARMACY - A.Y.: 2017/2018
- Course year: 3 - First cycle degree (DM 270) - Biomedical Laboratory techniques - A.Y.: 2016/2017
- Course year: 2 - First cycle degree (DM 270) - Imaging and Radiotherapy techniques - A.Y.: 2017/2018
Anno accademico di erogazione: 2017/2018
Anno accademico di erogazione: 2016/2017
Anno accademico di erogazione: 2015/2016
- Course year: 2 - Full cicle (5 years) - PHARMACY - A.Y.: 2014/2015
- DRUG SCIENCES A.Y. 2020/2021
- Full cicle (5 years) PHARMACY A.Y. 2020/2021
- DRUG SCIENCES A.Y. 2019/2020
- Full cicle (5 years) PHARMACY A.Y. 2019/2020
- Full cicle (5 years) PHARMACY A.Y. 2018/2019
- Full cicle (5 years) PHARMACY A.Y. 2017/2018
- Full cicle (5 years) PHARMACY A.Y. 2016/2017
- Full cicle (5 years) PHARMACY A.Y. 2015/2016
- Full cicle (5 years) PHARMACY A.Y. 2014/2015
Year: 2020Author/s: Quarta, Eride, Chierici, Veronica, Flammini, Lisa, Tognolini, Massimiliano, Barocelli, Elisabetta, Cantoni, Anna Maria, Sonvico, Fabio, Colombo, Gaia, Rossi, Alessandra, Bettini, Ruggero, Colombo, Paolo, Buttini, Francesca
Year: 2020Author/s: Giorgio C., Zanotti I., Lodola A., Tognolini M.
Drug-gut microbiota metabolic interactions: the case of UniPR1331, selective antagonist of the Eph-ephrin system, in miceYear: 2020Author/s: Ferlenghi F., Castelli R., Scalvini L., Giorgio C., Corrado M., Tognolini M., Mor M., Lodola A., Vacondio F.
Optimization of EphA2 antagonists based on a lithocholic acid core led to the identification of UniPR505, a new 3α-carbamoyloxy derivative with antiangiogenetic propertiesYear: 2020Author/s: Incerti M., Russo S., Corrado M., Giorgio C., Ballabeni V., Scalvini L., Callegari D., Castelli R., Vacondio F., Ferlenghi F., Tognolini M., Lodola A.
Year: 2020Author/s: Corrado M., Giorgio C., Barocelli E., Vittucci Marzetti G., Di Lecce R., Incerti M., Castelli R., Lodola A., Tognolini M.